Update on Phase III trial for Odanacatib, Merck’s investigational cat-K inhibitor for Osteoporosis
11 July 2012 | By Merck
Merck announced an update on the Phase III trial...
List view / Grid view
News
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide
11 July 2012 | By GlaxoSmithKline
Data has been received from the Phase III Harmony 8 study...
Lilly announces Pomaglumetad Methionil did not meet primary endpoint of clinical study
11 July 2012 | By Eli Lilly and Company
Eli Lilly and Company announced negative clinical trial results...
Abbott introduces OneLab, a novel integrated Web-based software platform
As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, today Abbott announced OneLab, a new, Web-based, integrated laboratory informatics solution.
Recent advances in controlled release, solubility, and ODT applications presented by Catalent expert
Michael J. Valazza R.Ph., Vice President, Global Modified Release Technologies, Catalent Pharma Solutions, will be presenting on “Recent Advances in Oral Granules and Fixed Dose Tablet technologies, OptiMeltTM Solubility Enhancement Solutions, and Oral Disintegrating Tablet applications,” on Sunday, July 15th from 10:15AM -11:15AM as part of a releasing technology workshop…
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
11 July 2012 | By GlaxoSmithKline
Phase III SINGLE study results...
Syrris’ Asia flow chemistry system joins select group of R&D 100 Award winners
10 July 2012 | By kdm communications limited
Syrris has won a prestigious 2012 R&D 100 Award for Asia...
Abbott announces new test for the management of patients with diabetes
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformité Européenne) for the Abbott ARCHITECT HbA1c…
Boehringer Ingelheim pursuing health care innovation – new collaboration with Healthrageous, Inc
10 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is concentrating on new business models...
Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc.
10 July 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb announced on Friday, June 29, 2012, its intent to acquire Amylin...
Lonza launches next generation GS Gene Expression System™
Lonza, a world leader in gene expression and biopharmaceutical development of protein therapeutics, announced today the launch of the new GS Xceed™ Gene Expression System.
Sanofi-aventis withdraws its marketing authorisation application for Mulsevo
9 July 2012 | By European Medicines Agency (EMA)
The EMA has been notified by Sanofi-aventis of its decision to withdraw its marketing authorisation application for Mulsevo...
B&W Tek launches new website with renewed focus on spectroscopy solutions
9 July 2012 | By B&W Tek
B&W Tek, Inc., is thrilled to introduce their exciting and intuitive new website...
Phenomenex UHPLC column protection system wins R&D 100 Award
9 July 2012 | By Phenomenex Inc
The SecurityGuard™ ULTRA UHPLC column protection system has been recognized as one of the top innovations of 2012...
Boehringer Ingelheim establishes translational research collaboration with Harvard University
9 July 2012 | By Boehringer Ingelheim
"We are very pleased to sponsor the joint research programs..."
